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Abstract
Parkinson disease (PD) is a complex neurodegenerative disorder influenced by both envi-
ronmental and genetic factors. While genome wide association studies have identified sev-
eral susceptibility loci, many causal variants and genes underlying these associations
remain undetermined. Identifying these is essential in order to gain mechanistic insight and
identify biological pathways that may be targeted therapeutically. We hypothesized that
gene-based enrichment of rare mutations is likely to be found within susceptibility loci for PD
and may help identify causal genes. Whole-exome sequencing data from two independent
cohorts were analyzed in tandem and by meta-analysis and a third cohort genotyped using
the NeuroX-array was used for replication analysis. We employed collapsing methods (bur-
den and the sequence kernel association test) to detect gene-based enrichment of rare, pro-
tein-altering variation within established PD susceptibility loci. Our analyses showed trends
for three genes (GALC, PARP9 and SEC23IP), but none of these survived multiple testing
correction. Our findings provide no evidence of rare mutation enrichment in genes within
PD-associated loci, in our datasets. While not excluding that rare mutations in these genes
may influence the risk of idiopathic PD, our results suggest that, if such effects exist, much
larger sequencing datasets will be required for their detection.
Introduction
Parkinson disease (PD) is a complex disorder influenced by the crosstalk between genetic and
environmental factors [1]. Monogenic causes account for a small fraction of cases, whereas the
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vast majority of patients have idiopathic disease. While genome-wide association studies
(GWAS) have revealed several susceptibility loci for idiopathic PD, these collectively explain
only a fraction of the disorder’s estimated heritability, and most have not been linked to path-
ways which can be targeted by therapies [2]. This is partly due to the uncertainty regarding
which genes actually drive the GWAS signals.
The associated variants in GWAS are typically located in noncoding regions of the genome
and assumed to be in linkage disequilibrium (LD) with causative variants in nearby genes [3].
Methods to identify candidate genes from GWAS range from simply choosing the closest gene
to more sophisticated algorithms [4], but all are, in essence, inferential by nature. Next genera-
tion sequencing technologies have enabled us to investigate the impact of rare genetic varia-
tion, which is theorized to explain parts of the “missing heritability” in complex diseases [5]. In
PD, rare variants have been implicated in sporadic disease both at the gene- [6] and pathway
level [7,8]. Whether rare variants can explain GWAS signals in PD, remains, however,
unknown.
We hypothesized that gene-based enrichment of rare, protein-altering variation is likely to
be found in regions tagged by single nucleotide polymorphisms (SNPs) associated with PD in
GWAS, and may help identify the causal genes driving these associations. To test our hypothe-
sis, we selected genes with variants in LD with associated SNPs from the most recent GWAS
meta-analysis[9], and tested for enrichment of rare, protein-altering variants in whole-exome
sequencing data from two independent cohorts.
Methods
Cohorts and sequencing
The Norwegian whole-exome sequencing (WES) cohort comprised 191 patients with PD from
the Norwegian ParkWest study [10] and 219 controls. The control group consisted of individ-
uals with testis cancer (n = 167) and acoustic neuroma (n = 52) who had been recruited and
examined at our hospital and had no clinical signs of neurodegenerative- or other neurological
disorders. DNA was extracted from blood by routine procedures and sequenced at HudsonAl-
pha Institute for Biotechnology (Huntsville, Alabama) on the Illumina HiSeq platform using
paired-end 100 bp sequencing and Roche-NimbleGen Sequence Capture EZ Exome v2 (173
controls) and v3 (all PD and 46 controls) capture kits. Reads were mapped to the hg19
(GRCh37) reference genome using BWA v0.6.2 [11], PCR duplicates removed with Picard
v1.118 [12], and the alignment refined using Genome Analysis Toolkit (GATK) v3.3.0 [13]
applying base quality score recalibration and realignment around indels recommended in the
GATK Best Practices workflow [14,15]. Variants were called in all samples using GATK Hap-
lotypeCaller [13] with default parameters. Next, Variant Quality Score Recalibration (VQSR)
was performed using 99.9% sensitivity threshold [13]. The remaining variants were filtered
against the intersection of capture targets (v2 and v3) using BEDtools [16] and VCFtools [17].
Variants with total depth below 10X were marked as unknown genotype (no-call) using
BCFtools [18]. In addition, we used a cutoff of at least 6 reads supporting each variant (alter-
nated allele). Indels were removed prior to downstream analyses. The depth distribution for all
variants and variants of interest is shown in S1 Fig.
Additional whole-exome sequencing data was obtained from the Parkinson Progression
Markers Initiative (PPMI) [19]. WES data was available from 640 individuals (459 cases and
181 controls). Control subjects were individuals without PD 30 years or older, without first
degree relatives with PD. Sequencing was performed on the Illumina HiSeq 2500 platform
using the Illumina Nextera Rapid Capture Expanded Exome Kit and paired-end 100 bp reads.
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Calling and alignment were performed by the PPMI. Indels were removed prior to variant
quality control using VCFTools [17].
SNP-chip data was obtained from the International Parkinson’s Disease Genomics Consor-
tium (IPDGC) (dbGaP Study Accession: phs000918.v1.p1). The dataset consisted of 11,402
individuals (5,540 cases and 5,862 controls) genotyped on the NeuroX array, comprising
approximately 240,000 standard Illumina exome variants and 24,000 custom variants focusing
on neurological diseases [20,21].
Individual and variant quality control
Sequencing and genotype data were recoded into binary PLINK input format, and quality con-
trol of individual and SNP data was performed for all three cohorts separately. Individuals
were excluded if they had an individual genotype missingness rate of> 2%, heterozygosity
outside +/- 3 standard deviations (calculated for common and rare variants separately), cryptic
relatedness (IBD > 0.2), conflicting sex assignment or non-European ancestry. Population
stratification was studies using multi-dimensional scaling against the HapMap populations
[22]. Variants were removed if they had a genotyping rate < 98%, different call rates in cases
and controls (p> 0.02) or departure from the Hardy-Weinberg equilibrium (p< 10−5). Only
autosomes were kept for downstream analyses. Principal component analysis was performed
using Eigensoft [23,24] with standard filtering settings. ANOVA of the 10 first principal com-
ponents was performed with the significance level set to p< 0.01. Significant principal compo-
nents were included as covariates in all downstream analyses. Outside of the principal
component analysis, all quality control procedures were performed using PLINK v1.90 [25]
and R [26].
Annotation and subset filtering
The datasets were annotated using ANNOVAR [27] according to the RefSeq gene transcripts,
and variants classified as nonsynonymous, stop-gain, stop-loss or splicing were extracted for
further analysis. Rare variants were defined as having a minor allele frequency (MAF) of< 1%
in the non-Finnish European population in gnomAD [28].
Selection of genes of interest
Genomic regions associated with PD where extracted from the largest and most recent, to
date, meta-analysis of GWASes, which identified 90 SNPs associated with PD at genome-wide
significance level [9]. We defined genes of interest as any gene containing a variant in LD
within a 2 megabase window around any of these 90 SNPs, with the threshold of LD set to R2
> 0.5. If a variant in LD was localized in an intergenic region, the nearest gene was included.
LD calculations were available from the supplementary material of the original study [9], and a
total of 303 genes fit the inclusion criteria (S1 Table).
Genetic association analyses
For each cohort, genes of interest were analyzed by two different tests: the burden test and the
sequence kernel association test (SKAT) [29], using the SKAT R package v1.3.2.1 [30] with
default settings. Statistically significant principal components, as determined by an ANOVA of
the first 10 principal components with significance level cutoff set to p< 0.01, were added as
covariates to all downstream analyses. Only genes with variants in both WES cohorts (Park-
West and PPMI) and at least two or more variants across cohorts were included. The meta-
analysis was performed using the MetaSKAT R package v0.60 [31], using the same burden test
PLOS ONE No evidence for rare variant enrichment in Parkinson disease associated loci
PLOS ONE | https://doi.org/10.1371/journal.pone.0239824 October 1, 2020 3 / 9
and SKAT as described above in a meta-analysis framework. For the meta-analysis, we hypoth-
esized that genetic effects should be homogenous across studies, meaning that the same muta-
tion should have the same direction of effect in both cohorts. NeuroX was used as a replication
cohort for the results from the WES analyses, and analyzed using the same methods. Only vari-
ants defined as rare were included. All p-values were corrected for multiple comparisons using
FDR (Benjamini-Hochberg) [32].
Gene set analyses
In addition to the single gene analyses, enrichment of genetic variation across all genes of
interest was explored in a gene set analysis. Only rare variants were included, and the com-
bined gene set was analyzed by burden and SKAT tests using the same methods and statistical
tools as for the single gene analyses. A subset of loss-of-function (LoF) variants (containing
only splicing, stop-loss and stop-gain variants) was extracted and similarly analyzed.
Ethical considerations
These studies were approved by the Regional Committee for Medical and Health Research
Ethics, Western Norway (REK 131/04), and all subjects gave written, informed consent. All
research was performed in accordance with the relevant guidelines and regulations.
Results
Using the inclusion criteria outlined previously, 168 genes of interest were analyzed in the sin-
gle gene analyses, comprising a total of 543 rare nonsynonymous, stop-gain, stop-loss or splic-
ing variants in the ParkWest cohort, and 1135 in the PPMI cohort. 160 of these genes were
available for replication analysis in the NeuroX dataset, comprising a total of 1380 variants.
For the gene set analysis, the number of included variants was 554 in the ParkWest, 1341 in
the PPMI and 1534 in the NeuroX cohorts. A total of 14 LoF variants were identified in the
ParkWest cohort, 17 in the PPMI cohort and 40 in the NeuroX cohort.
Gene-based analyses indicated three genes with nominally significant p-values (uncorrected
p< 0.05) across multiple cohorts: GALC, SEC23IP and PARP9. However, no gene reached sta-
tistical significance surviving multiple testing correction in either of the cohorts or the meta-
analysis (see S2 Table). Similarly, there were no statistically significant results in the gene set
analyses (see S3 Table). The top results of the gene enrichment analyses, ranked by nominal p-
value in the meta-analysis, are shown in the Tables 1 and 2.
Discussion
Our analyses revealed no statistically significant enrichment of rare variants in genes impli-
cated by previous GWAS in PD. Three genes (GALC, SEC23IP and PARP9) showed trends
across multiple cohorts, but none survived multiple testing correction. Nalls et al [9] con-
ducted rare variant burden analysis for SEC23IP finding no enrichment signal. Thus, it is
highly unlikely that SEC23IP is involved in PD. The variant tagging PARP9 (rs55961674) is a
weak expression quantitative trait loci (eQTL) for PARP9 in some tissues (nerve and thyroid)
[33]. However, it is also a strong splicing QTL (sQTL) for KPNA1, suggesting that this is a
more likely candidate gene. Finally, the variant tagging GALC (rs979812) is a strong eQTL for
GALC, supporting a potential role in PD [33]. GALC encodes the enzyme galactocerebrosidase,
and mutations in this gene cause Krabbe disease, a lysosomal storage disorder [34]. Current
evidence suggests that lysosomal dysfunction plays a key role in PD [35], and rare mutations
in a broad range of genes causing lysosomal storage disorders have been associated with PD
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[7]. Mutations of GBA in particular, the gene encoding the enzyme glucosylcerebrosidase that
carries out a very similar reaction to that of galactocerebrosidase, are the most common
genetic risk factor for PD and this association is driven by both common [36] and rare variants
[37]. A role for GALC in α-synucleinopathies is therefore not farfetched [38].
Taken together, our findings provide no evidence of rare mutation enrichment in PD
GWAS loci, in our datasets. These results do not support our initial hypothesis that gene-
based enrichment of rare mutations can be helpful in identifying causal genes in PD-associated
loci. It should be stressed that these findings do not disprove the hypothesis that rare muta-
tions in these genes may influence the risk of idiopathic PD. They do, however, suggest that if
such effects exist, much larger sequencing datasets will be required for their detection.
A few studies with similar approaches to ours have previously been published, using older
GWAS data. Foo et al [39] probed 39 genes implicated in PD by GWAS and described enrich-
ment of rare missense variation in LRRK2. Sandor et al [40] investigated 329 genes located
within GWAS loci, and detected a possible enrichment of missense variation, including both
common and rare mutations in their analysis, across the complete gene set. Finally, Jansen
et al [41] used a Prix fixe strategy to select one candidate gene per GWAS locus, and detected
Table 1. Top results for burden-based gene enrichment analyses.
Gene ParkWest PPMI Meta NeuroX
Variants P-value FDR Variants P-value FDR Variants P-value FDR Variants P-value FDR
SEC23IP 3 0.0276 0.9035 9 0.0332 0.9191 11 0.0040 0.6669 10 0.6819 0.9037
PARP9 3 0.0819 0.9035 9 0.0730 0.9191 11 0.0110 0.7058 7 0.0908 0.6353
GALC 4 0.8111 0.9035 5 0.0032 0.5335 8 0.0210 0.7058 7 0.2607 0.8180
NFKB2 1 0.0180 0.9035 7 0.2543 0.9191 7 0.0333 0.7058 6 0.7477 0.9037
ATP2A1 2 0.0518 0.9035 10 0.2232 0.9191 12 0.0416 0.7058 7 0.6897 0.9037
PBXIP1 1 0.3142 0.9035 8 0.0656 0.9191 9 0.0457 0.7058 10 0.6148 0.9037
CASR 1 0.6461 0.9035 4 0.0276 0.9191 4 0.0457 0.7058 6 0.5906 0.9037
ITGA8 2 0.1473 0.9035 10 0.1905 0.9191 12 0.0533 0.7058 18 0.6969 0.9037
VPS13C 26 0.2533 0.9035 24 0.1276 0.9191 42 0.0557 0.7058 49 0.0636 0.5420
CTSB 3 0.9743 0.9801 15 0.0279 0.9191 17 0.0688 0.7058 10 0.4903 0.9037
Genes are ranked by p-value in the meta-analysis. The FDR-column contains p-values after applying false discovery rate-correction.
https://doi.org/10.1371/journal.pone.0239824.t001
Table 2. Top results from SKAT-based gene enrichment analyses.
Gene ParkWest PPMI Meta NeuroX
Variants P-value FDR Variants P-value FDR Variants P-value FDR Variants P-value FDR
CASR 1 0.6461 0.9008 4 0.0012 0.2089 4 0.0029 0.4900 6 0.7926 0.9880
PARP9 3 0.1087 0.9008 9 0.1820 0.9393 11 0.0215 0.8873 7 0.0311 0.5528
GALC 4 0.0460 0.9008 5 0.0366 0.9393 8 0.0311 0.8873 7 0.8539 0.9880
NFKB2 1 0.0180 0.9008 7 0.9714 0.9944 7 0.0381 0.8873 6 0.2684 0.9257
SEC23IP 3 0.1313 0.9008 9 0.1113 0.9393 11 0.0469 0.8873 10 0.3037 0.9320
SCARB2 2 0.1983 0.9008 3 0.4048 0.9393 4 0.0829 0.8873 11 0.5043 0.9613
BTNL2 1 0.7423 0.9008 8 0.1152 0.9393 9 0.1085 0.8873 14 0.3768 0.9494
CTSB 3 0.4239 0.9008 15 0.1788 0.9393 17 0.1153 0.8873 10 0.0664 0.7225
PAM 5 0.1454 0.9008 13 0.2638 0.9393 17 0.1188 0.8873 11 0.8316 0.9880
TUFM 1 0.3609 0.9008 2 0.5208 0.9393 2 0.1205 0.8873 1 0.1826 0.9257
Genes are ranked by p-value in the meta-analysis. The FDR-column contains p-values after applying false discovery rate-correction.
https://doi.org/10.1371/journal.pone.0239824.t002
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rare variation association signals in LRRK2, STBD1 and SPATA19. While we could not repli-
cate enrichment for any of these genes in our datasets, it should be noted that our sample size
(n = 1050) is smaller than that of Jansen et al [6,41].
In addition to rare variant enrichment analyses, several other methodologies have been
employed to nominate causal genes from GWAS loci. eQTL studies integrate genotype and
gene expression date, to identify genes whose expression is regulated by PD associated SNPs
[42–46]. The effect of non-coding genetic variation on splicing of pre-mRNA (splicing QTLs
or sQTLs) has also recently been highlighted and used to further explore possible causal genes
in PD [47]. Finally, epigenetic quantitative trait loci, such as DNA methylation (mQTL), have
also been used in combination with GWAS and eQTL data with variable success [48].
PD is a complex disease of heterogeneous etiology. While there is a clear genetic compo-
nent, as evidenced by twin studies [49], known risk loci are primarily common mutations
which, collectively, only explain a fraction of the total estimated heritability [9]. As for other
complex disorders, much of the unexplained heritability is believed to be caused by rare vari-
ants [50]. Multiple studies have linked common mutations, either through the use of polygenic
risk scores [51] or machine learning algorithms [42], to motor progression and cognitive
decline. In addition, common genetic variation has also been shown to impact drug respon-
siveness in PD [52]. Similar applications of rare variants could potentially increase the predic-
tive precision of these models and provide clinicians with a powerful tool to individualize
treatment and follow-up for PD patients.
In conclusion, our results indicate that rare variant enrichment alone is unlikely to be help-
ful in identifying causal risk genes for PD in small to moderately sized cohorts. Larger studies
are needed to determine if rare variant enrichment with small effect sizes are present in these
genes. Future studies will likely need to integrate multiple types of data, including GWAS,
sequencing and various forms of QTL analyses as well as functional experiments in order to
better characterize the effects of rare coding variation in PD and identify novel genes and bio-
logical pathways.
Supporting information
S1 Fig. Variant depth distribution. A) Depth distribution of all variants called across all sam-
ples. B) Depth distribution for the subset of variants called within the predefined regions of
interest across all samples. Red bars represent heterozygous variants (0/1), and blue bars repre-
sent homozygous (1/1) variants. The vertical dashed line represents the cutoff of minimum 10
reads employed in the analyses.
(PDF)
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S2 Table. Complete results from gene-based rare variant enrichment analyses.
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S3 Table. Gene set analyses.
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